Yeztugo is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection

This content originally appeared on Gilead.com. View the full article here.

Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo (lenacapavir)—the company’s injectable HIV-1 capsid inhibitor—as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly option available in the United States for people who need or want PrEP. Data show that ≥99.9% of participants who received Yeztugo in the Phase 3 PURPOSE 1 and PURPOSE 2 trials remained HIV negative.

“This is a historic day in the decades-long fight against HIV. Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences. “This is a medicine that only needs to be given twice a year and has shown remarkable outcomes in clinical studies, which means it could transform HIV prevention. Gilead scientists have made it their life’s work to end HIV and now, with the FDA approval of Yeztugo and in collaboration with our many partners, we can help to make that goal a reality.”

The first PrEP medication, which was also developed by Gilead, was approved in the U.S. in 2012. However, data from the Centers for Disease Control and Prevention (CDC) show that, in 2022 (the most recent year with available data), only about 1 in 3 (36%) people in the U.S. who met the CDC’s eligibility criteria for PrEP were prescribed a form of PrEP. CDC data show that all populations in the U.S. are not yet using PrEP at rates that could end transmission of the virus at the population level, with particular gaps for women, Black/African American and Hispanic/Latino people, and people in the U.S. South. Data also show that barriers including adherence challenges, stigma and low awareness of existing PrEP options—by both healthcare providers and consumers—contribute to this low uptake of PrEP across multiple populations. The potential impact of this limited uptake, adherence and access is underscored by the fact that, in 2023, more than 100 people were diagnosed with HIV every day in the U.S.

“Yeztugo could be the transformative PrEP option we’ve been waiting for—offering the potential to boost PrEP uptake and persistence and adding a powerful new tool in our mission to end the HIV epidemic,” said Carlos del Rio, MD, Distinguished Professor of Medicine in the Division of Infectious Diseases at Emory University School of Medicine and Co-Director of the Emory Center for AIDS Research in Atlanta. “A twice-yearly injection could greatly address key barriers like adherence and stigma, which individuals on more frequent PrEP dosing regimens, especially daily oral PrEP, can face. We also know that, in research, many people who need or want PrEP preferred less frequent dosing.”

Access the full article on the Gilead Sciences, Inc website: Yeztugo Lenacapavir Is Now the First and Only FDA Approved HIV Prevention Option Offering 6 Months of Protection

Notice of Updated Effective Date for the 2024 NIH Public Access Policy

This content originally appeared on NIH Office of Science Policy. View the full article here.

Increasing access to publications resulting from federally funded research offers many benefits to the scientific community and the public. Access can accelerate research, generate higher quality scientific results, encourage greater scientific integrity, and enable future inquiry, discovery, and translation for NIH-supported research. Importantly, these efforts also uphold NIH’s commitment to responsible stewardship of the Nation’s investment in biomedical research by improving transparency and accessibility of taxpayer-funded research.

2024 NIH Public Access Policy (December 2024)

On December 17, 2024, NIH released its updated 2024 Public Access Policy. The Public Access Policy was informed by public feedback, including comments received in response to the NIH Draft Public Access Policy. The 2024 NIH Public Access Policy is in keeping with the White House OSTP memo “Ensuring Free, Immediate, and Equitable Access to Federally Funded Research.”

NIH’s default position is maximum transparency regarding research and research findings. This notice updates the Effective Date of the 2024 NIH Public Access Policy, NOT-OD-25-047, to July 1, 2025 at which time it will replace the 2008 Public Access Policy. All other aspects of the Policy remain the same. The Policy will continue to apply to any author accepted manuscript accepted for publication in a journal that is the result of funding by NIH in whole or in part through a grant or cooperative agreement, including training grants, a contract, an other transaction, NIH intramural research, or the official work of an NIH employee. Author accepted manuscripts meeting this qualification and with acceptance dates on or after July 1, 2025, are subject to the Policy.

Supplemental Guidance, at Notice NOT-OD-25-049 and Notice NOT-OD-25-048, will continue to apply. More information to assist in the implementation of the Policy will be available at: https://sharing.nih.gov/public-access-policy/.

National Asian & Pacific Islander HIV/AIDS Awareness Day 2025

On May 19, 2025 – CHIPTS will join partners across the U.S. in observing National Asian & Pacific Islander HIV/AIDS Awareness Day, a day to raise awareness and promote action against HIV and AIDS within Asian and Pacific Islander (API) communities. It also emphasizes the importance of education, quality care, and addressing stigma and related health conditions.

NAPIHAAD is an important reminder of the ongoing efforts to promote HIV prevention, testing, and treatment among Asian, Native Hawaiian, and Pacific Islander people and an opportunity to share important resources that can help combat the HIV epidemic. Please use the resources below to support the ongoing efforts to reduce HIV and AIDS in this community.

As an AIDS Research Center committed to investigating and addressing HIV and related challenges, CHIPTS is pleased to share recent research by Dr. Wei-Ti Chen, CP Core Affiliate, which specifically explores and addresses these barriers within Asian communities.

Huang, J., Lin, Y., Fu, Y., Xu, Z., Hong, H., Arbing, R., Chen, W. T., Wang, A., & Huang, F. (2024). A longitudinal network analysis of interaction factors among Chinese women at high risk for perinatal depression. Midwifery, 139, 104187.

Chen, W. T., Sun, W., Huang, F., Shiu, C. S., Kim, B., Candelario, J., Toma, L., Wu, G., & Ah-Yune, J. (2024). Lost in Translation: Impact of Language Barriers and Facilitators on the Health Care of Asian Americans Living with HIVJournal of racial and ethnic health disparities11(4), 2064–2072.

Chen, W. T., & Barbour, R. (2023). Male and female Asians living with HIV: a text-mining analysis comparing their concerns. Frontiers in psychology14, 1114731.

Stay Updated on the Latest NIH Grants and Funding Policies

This content originally appeared on NIH.Gov. View the full article here.

Stay Updated on Evolving NIH Grants and Funding Policies

NIH continues to update their grants and funding processes in response to shifting agency priorities and federal guidance. Key updates include changes to application requirements – such as revised review criteria and procedures for fellowships, training, and conference grant submissions. Additionally, updates have been made to application forms (FORMS-I), reporting requirements, and the posting of new funding opportunities.

For the most current information – including details on communications, applications, reviews, awards, and reporting – please visit the NIH Grants and Funding Information Status page. This page is updated regularly, so check back often for the latest developments.

Additional updates:

  1. NIH also announced a postponement of the May 25, 2025, implementation of the Common Forms for all applications and Research Performance Progress Reports (RPPRs). NIH will issue future Guide Notices outlining the new effective date and additional implementation details as they are finalized.
  2. NIH applicants and recipients must continue to use the current NIH Biosketchand Other Support format pages for applications, Just-in-Time (JIT) and RPPRs

 

HRSA’s Aging and HIV Initiative Launching Webinar Series in May

This content originally appeared on TargetHIV. View the full article here.

Summary:

The kick-off of a five-part webinar series in a HRSA aging and HIV initiative will be held May 13th.

The series is part of the HRSA Ryan White HIV/AIDS Program Part F SPNS Aging with HIV Initiative that supports and evaluates emerging interventions to comprehensively screen and manage comorbidities, geriatric conditions, behavioral health, and psychosocial needs of people with HIV aged 50 years and older.

SPNS Aging with HIV Initiative – Part F

The Emerging Strategies to Improve Health Outcomes for People Aging with HIV (Aging with HIV Initiative) supports and evaluates groundbreaking interventions that seek to improve the well-being of people with HIV ages 50 and older served by the Ryan White HIV/AIDS Program (RWHAP).

Funded by HRSA’s RWHAP Part F: Special Projects of National Significance (SPNS), the interventions being tested at each Aging with HIV Initiative demonstration site employ the HRSA HIV/AIDS Bureau (HAB) implementation science framework to:

  • Implement emerging strategies that comprehensively screen and manage comorbidities, geriatric conditions, behavioral health, and psychosocial needs of people 50 years and older with HIV.
  • Assess the uptake and integration of emerging strategies.
  • Understand implementation processes, including assessing specific implementation strategies.
  • Understand and document broader contextual factors affecting implementation.
  • Evaluate the impact of the emerging strategies.
  • Document and disseminate the emerging strategies.

Learn more: https://targethiv.org/spns/aging

HRSA Aging and HIV Webinar Series

This session, “Enhancing Workforce Capacity for Care in HIV and Aging Populations,” is the first webinar in a five-part series, which will focus on enhancing workforce capacity in HIV and aging care. Experts from University of Chicago and Yale University will discuss effective strategies for training healthcare providers, addressing workforce gaps, and implementing best practices in HIV and aging care.

Learning objectives:

  • Understand the essential workforce competencies for providing quality care to aging adults with HIV.
  • Learn about successful training initiatives from demonstration sites.
  • Explore strategies to bridge workforce gaps and sustain quality care services.

Healthcare professionals, community health workers, social workers, policymakers, educators & researchers in public health, gerontology, and social work, and others interested in aging and HIV care are strongly encouraged to attend the first webinar session.

Register for the May 13 webinar.

CROI 2025 Recap: Abstract eBook and Resources Available

This content originally appeared on TargetHIV. View the full article here.

From CROI (Excerpts)

Dear Colleague:

The Abstract eBook, session recordings (webcasts), and additional materials from the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) are now publicly accessible at CROI 2025 Resources – CROIconference.org.

In the coming months, key research highlights from CROI 2025 will be featured through a variety of formats, including webinars, podcasts, CME-accredited in-person and on-demand courses, and journal articles in Topics in Antiviral Medicine™.

Below is an overview of the available CROI 2025 resources. Sign up for upcoming events and explore the content to deepen your understanding of the latest data and its clinical implications. Many of these resources are available at no cost.

Our Voices: Video Testimonials, Podcasts, and YouTube

In addition to showcasing more than 1000 presentations of the latest and most impactful research, CROI 2025 amplified many powerful voices in support of scientific progress. These special features are now available as podcasts and on YouTube. Watch, listen, and help spread the word—whether by sharing individual episodes or the full collection at Our Voices – CROIconference.org.

Going anti–Viral Podcasts

Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections produced by IAS–USA. Several current and upcoming episodes were recorded live from CROI.

CROI Review Articles for CME

Review articles will be published in Topics in Antiviral Medicine™, the journal of the International Antiviral Society–USA, this spring. See the CROI 2025 Review Articles page to access the articles ahead of the issue (as they become available).

CME Courses (On-Demand)

The IAS–USA CME courses from New York and Atlanta feature new data and exclusive highlights of important clinical updates from CROI. These are exciting opportunities to stay at the forefront of the latest information on HIV management. Visit On-Demand HIV Courses (2025) – IAS-USA.org

In Case You Missed It: Key Highlights from CROI 2025

On Monday, April 21, from 2–3 PM PT, CHIPTS hosted a virtual event entitled “In Case You Missed It: Key Highlights from CROI 2025.” This session aimed to spotlight key abstracts from the 2025 Conference on Retroviruses and Opportunistic Infections (CROI), hand-selected by CHIPTS scientists – Drs. Dubov, Gorbach, Landovitz, and Shoptaw. Our featured CHIPTS scientists for the ICYMI, shared the innovative research they found particularly compelling for the CHIPTS community.

The session moderated by Dr. Cathy Reback, welcomed a broad audience, including students, community members, healthcare providers, policymakers, and researchers, creating a space to explore how new scientific findings can inform and strengthen collective efforts to end the HIV epidemic.

See the list of featured abstracts below, along with links to the corresponding slides and posters available on the CROI website.

1. 160 – Missed Opportunities for Syphilis Diagnosis with Targeted Compared to Universal Screening – Slides Video
2. 157 – Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention – Slides Video
3. 192 – ImPrEP CAB Brasil: Enhancing PrEP Coverage with CAB-LA in Young Key Populations – Slides Video

———-
1. 1178 – National HIV Self-Test Distribution Program: HIV Testing, Diagnosis, and Treatment – Slides Video
2. 187 – How do Repeated Financial Incentives Affect HIV Care-Seeking Behaviors Over Time in Tanzania? – Slides Video
3. 1145 – Unstable Housing, Methamphetamine Use, and HIV Incidence among Racial and Ethnic Minority Men – Poster

———-
1. 154 – Pharmacokinetics and Safety of Once-Yearly Formulations of Lenacapavir – Slides Video
2. 194 – Adherence to F/TAF in Cisgender Women Prevents HIV With Low Risk of Resistance or Diagnostic Delay – Slides Video
3. 200 – Ensitrelvir to Prevent COVID-19 in Households: SCORPIO-PEP Phase III Placebo-Controlled Trial Results – Slides Video

———-
1. 750 – High HCV reinfection rates may mask true sustained virologic response in People who inject drugs – Poster

National Women and Girls HIV/AIDS Awareness Day 2025

March 10, 2025 – Today, CHIPTS joins partners across the country in observing National Women and Girls HIV/AIDS Awareness Day, a day when we reaffirm our commitment to addressing the barriers to HIV/AIDS treatment for women and girls. In honor of #NWGHAAD, CHIPTS CAB Co-Chair Natalie Sanchez shares a reflection of todays’ awareness day and highlights the Confessions: HIV Positive Women podcast. Learn more below.

UCLA Los Angeles Family AIDS Network is once again partnering with Christie’s Place in San Diego for a new season of Confessions: HIV Positive Women, launching on March 10 in recognition of National Women and Girls HIV/AIDS Awareness Day (NWGHAAD). This day serves as a crucial reminder of the impact of HIV on women and girls, while emphasizing the importance of education, prevention, and access to care.

In the U.S., nearly 23% of people living with HIV are women, with Black and Latina women disproportionately affected due to systemic barriers in healthcare, stigma, and lack of access to early testing and treatment. Young women, in particular, face challenges in receiving timely diagnoses and navigating the complexities of living with HIV. NWGHAAD sheds light on these disparities and encourages conversations that empower women and girls to prioritize their health and well-being.

This season of Confessions: HIV Positive Women will explore the deeply personal journeys of women at different life stages, each navigating the realities of living with HIV. Listeners will meet a young woman who was recently diagnosed at just 21 years old, a lifelong survivor who has lived with HIV since birth, and women who are now facing the unique challenges of aging with the condition. Their stories are a powerful testament to resilience, strength, and the evolving experiences of women living with HIV.

Marilynn Ramos, a participant from Season 1 and now a Peer Educator, reflects on her experience:

“Participating in the Confessions Mujeres VIH+ podcast has been a life-changing experience. I went from being a caterpillar, unsure of where to go or how to move forward, to transforming into a butterfly, free to embrace my story and share it with others. Telling my truth has been an act of liberation, and through it, I have found my voice. This podcast has not only healed me, but it has also given me the chance to offer other women a glimpse of hope they might need to keep going. It has changed my life, and I am honored to be part of something that can help change the lives of others.”

Through open and honest storytelling, Confessions: HIV Positive Women continues to break down stigma, amplify women’s voices, and foster a supportive community for those impacted by HIV. As we recognize NWGHAAD, let us reaffirm our commitment to raising awareness, advocating for equitable healthcare, and ensuring that all women and girls – regardless of their circumstances – have access to the resources and support they need to live full, healthy lives.

Links to Podcast:

Confessions

Confessions Podcast – Apple Podcasts

CHIPTS at the 32nd Conference on Retroviruses and Opportunistic Infections (CROI)

The 32nd Conference on Retroviruses and Opportunistic Infections (CROI) is being held on March 9 -12, 2025, in San Francisco, California. Learn more about CROI 2025 and the exciting work of our CHIPTS scientists featured at the conference below.

 

What is CROI 2025?

CROI 2025 provides a forum for scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. CROI is the preeminent HIV research meeting in the world and includes up to 4,000 HIV research and care leaders internationally. CROI has facilitated the presentation of important discoveries in the field, thereby accelerating progress in HIV and AIDS research.

 

CHIPTS at CROI 2025

Several CHIPTS scientists will be sharing exciting research findings and project updates at CROI 2025, contributing to the dissemination of crucial information that advances HIV prevention and treatment initiatives globally. We are delighted to highlight workshops, oral abstracts, and poster abstracts featuring the important work of our CHIPTS scientists.

 

Sunday, March 9, 2025

Raphael Landovitz (Moderator)

Workshop 01 – Scott M. Hammer Workshop for New Investigators and Trainees

Session Start: 8:30 AM (San Francisco Ballroom B)

 

Monday, March 10, 2025

Kara Chew

Poster Session H1 – HIV Resistance to bNAbs, Cabotegravir, GS 1720, and Other Agents

Session Start: 2:30 PM (Poster Hall)

725 – Effect of SNG001, Inhaled IFN-β1a, on SARS-CoV-2 Diversity and Evolution

 

Raphael Landovitz

Poster Session K2 – Hypertension

Session Start: 2:30 PM (Poster Hall)

820 – No Increased Risk for Hypertension With CAB-LA Compared to TDF/FTC for PrEP: Results From HPTN 084

 

Kara Chew

Poster Session-M1 – PASC: Natural History and Classification Systems

Session Start: 2:30 PM (Poster Hall)

921 – Assessing the Burden of Long COVID in Persons With HIV Using the RECOVER Scoring System

 

Dvora L. Joseph Davey

Poster Session T1 – Still Here: Syphilis

Session Start: 2:30 PM (Poster Hall)

1249 – Risk Factors for Incomplete Treatment for Syphilis in Pregnant Oral PrEP Users in South Africa

 

Tuesday, March 11, 2025

Kara Chew

Oral Abstract Session 06 – Immunology and Vaccines

Session Start: 10:00 AM (San Francisco Ballroom C)

142 – Profiling Therapeutic Vaccine-Driven HIV-Specific CD8 T Cells With Single-Cell TCR Sequencing Assays

 

Dvora L. Joseph Davey, Kathryn L. Dovel, and Thomas Coates

Oral Abstract Session 08 – New Frontiers in STI Prevention

Session Start: 10:00 AM (San Francisco Ballroom D)

166 – Impact of Urine TFV Testing on PrEP Adherence in South African Pregnant and Postpartum Women: An RCT

 

Kathryn L. Dovel

Poster Session Q01 – The HIV Care and Prevention Cascades: Novel Insights

Session Start: 2:30 PM (Poster Hall)

1086 – High Burden of Untreated HIV in Malawian Fishermen: Prospective Data From a Cluster Randomized Trial

 

Dvora L. Joseph Davey

Poster Session T4 – Global STI Epidemiology

Session Start: 2:30 PM (Poster Hall)

1265 – Diagnostic Screening and Treatment of Curable STIs in Pregnancy and Impact on Pregnancy Outcomes

 

Wednesday, March 12, 2025

Steve Shoptaw

Oral Abstract Session 11 – Gaps and Solutions in the HIV Response

Session Start: 10:00 AM (San Francisco Ballroom A)

183 – Preliminary Efficacy for HPTN 094: 26-Week RCT of Integrated Strategies for People Who Inject Drugs

 

Kathryn L. Dovel and Thomas Coates

Oral Abstract Session 11 – Gaps and Solutions in the HIV Response

Session Start: 10:00 AM (San Francisco Ballroom A)

185 – Low-Cost Counseling Achieves Positive Outcomes for Malawi Men Disengaged From Care: Randomized Trial

 

Raphael J. Landovitz

Oral Abstract Session 12 – Expanding the Prevention Toolbox

Session Start: 10:00 AM (San Francisco Ballroom D)

192 – ImPrEP CAB Brasil: Enhancing PrEP Coverage With CAB-LA in Young Key Populations

193 – Estimation of Prevention-Effective CAB-LA Concentrations Among MSM/TGW in HPTN 083

197 – Response to HIV Treatment After Long-Acting Cabotegravir Preexposure Prophylaxis in HPTN 083

 

Raphael J. Landovitz

Poster Session F3 – Pharmacokinetics in the Real World: Long-Acting Drugs, Alternative Matrices, and Adherence

Session Start: 2:30 PM (Poster Hall)

653 – TFV-DP Is Associated With Baseline Virologic Suppression in PWH on TAF: Results From ACTG A5359

 

Raphael J. Landovitz

Poster Session G3 – ART in Vulnerable and Treatment – Experienced Populations

Session Start: 2:30 PM (Poster Hall)

692 – A5359: Decreasing Oral Induction Duration in Support of LAI ART Use With Hardly Reached Populations

 

Kara Chew

Poster Session G5 – Antiviral Therapy for SARS-CoV-2

Session Start: 2:30 PM (Poster Hall)

713 – SARS-CoV-2 Ensitrelvir Resistance-Associated Mutations in Phase III Randomized Clinical Trial

 

Dvora L. Joseph Davey and Kathryn L. Dovel

Poster Session O5 – HIV Acquisition and Prevention During Pregnancy and Breastfeeding

Session Start: 2:30 PM (Poster Hall)

1009 – PrEP Adherence and Acceptability of Urine Tenofovir Testing in Pregnant and Postpartum Women

 

Steve Shoptaw and Pamina M. Gorbach

Poster Session Q10 – HIV and Substance Use

Session Start: 2:30 PM (Poster Hall)

1145 – Unstable Housing, Methamphetamine Use, and HIV Incidence Among Racial and Ethnic Minority Men

1146 – Substance Use Is Associated With Higher HIV Viral Load and Reduced Viral Suppression in 6 US Cohorts

 

Raphael J. Landovitz

Poster Session R3 – Challenging and Innovative HIV Testing

Session Start: 2:30 PM (Poster Hall)

1193 – Use of DNA Profiling to Resolve Discrepant HIV Tests in the Setting of Injectable Cabotegravir PrEP

2025 CHIPTS HIV Next Generation Conference Recap

The 2025 CHIPTS HIV Next Generation Conference welcomed over 150 attendees from academic institutions, community-based organizations, health care institutions, and other organizations working to end the HIV epidemic at the California Endowment on Friday, January 31, 2025. The conference included engaging oral and poster presentations, lively discussions, and networking opportunities to support the next generation of HIV researchers and service providers.

CHIPTS Development Core Co-Director Dallas Swendeman, PhD, facilitated this year’s conference and provided a warm welcome to participants. CHIPTS Director Steve Shoptaw, PhD, followed with opening remarks setting the tone for an exciting conference. He echoed the conference’s goals with a powerful statement: “Today is to talk about science and solutions that helps our communities, and to use this conference as a way to link and work together.”

Jerry John Ouner, PhD, RN, FAAN, Associate Professor, University of California San Francisco, offered an engaging and insightful opening plenary exploring how water insecurity and extreme weather events such as droughts, precipitation anomalies, and floods may influence HIV treatment. He highlighted how these factors could affect ART adherence, viral load suppression, and the prevalence of opportunistic infections among people living with HIV.

Throughout the day, there were four sets of oral presentations with panel discussions. The first panel was moderated by CHIPTS Combination Prevention Core Affiliate Michael Li, PhD, and centered on projects aimed at improving treatment adherence and viral suppression. The second set of oral presentations moderated by CHIPTS Combination Prevention Core Scientist Laura Bogart, PhD, focused on linkage and retention among people living with HIV. CHIPTS Methods Core Director Sung-Jae Lee, PhD, moderated the third panel on HIV testing, prevention, and PrEP. The fourth panel moderated by CHIPTS Policy Impact Core Co-Director Ayako Miyashita Ochoa, JD, led a discussion on the impact of local California policies and ballots on communities affected by HIV. The conference further featured a fantastic group of poster presentations highlighting innovative research and evaluation projects to support efforts to end the HIV epidemic.

The projects, The Intersection of Place and Health: Neighborhood and Socio-Economic Determinants of Viral Suppression (oral) and Black Feminist Strategies in HIV and Mental Health Care: A Literature Review (poster) won attendee votes for favorite oral and poster presentations respectively. To close the conference, CHIPTS Development Core Director Norweeta Milburn, PhD, congratulated this year’s outstanding presenters and encouraged participants to continue their commitment to new ideas and collaborations as we work together to end the HIV epidemic.

A complete list of oral presentations with descriptions, PowerPoint slides, and photo highlights from the conference are provided below.

Check out our photo gallery of the conference on our Facebook page: https://tinyurl.com/pvcp7hbz

—————————————–

Opening Plenary:

Jerry John Ouner, PhD, RN, FAAN, Associate Professor, University of California San Francisco

Presentation Title: Impact Of Water Insecurity and Extreme Weather Events on HIV Treatment Outcome

Presentation Summary: The presentation will focus on the influence of water insecurity and extreme weather events such as droughts, precipitation anomalies, and flood on HIV treatment. Dr. Ouner will highlight how water insecurity and extreme weather events affect adherence to antiretroviral therapy, viral load suppression and occurrences of opportunistic infection among people living with HIV.

 

Oral Panel 1 – Adherence and Viral Suppression:

1. Brendon Chau, MS

Presentation Title: Shifting from in-person to expanded telehealth delivery of medical care coordination for people with HIV: Impact on viral suppression

Presentation Summary: We model longitudinal trends in viral suppression before and after the transition to telehealth services during COVID-19 pandemic. The expected probability of viral suppression was not negatively impacted by tele-health adoption.

2. Stephen D. Ramos, PhD

Presentation Title: Adherence Self-Efficacy as a Conditional Mediator Between Internalized Heterosexism and Antiretroviral Medication Adherence: The Role of Hazardous Alcohol Use in Young Black Sexual Minority Men with HIV (YBSMM+) 

Presentation Summary: We found that internalized heterosexism is indirectly associated with self-reported ART adherence, via adherence self-efficacy. This mediating effect is strongest among participants who showed hazardous alcohol use. This underscores a contextualized understanding of these associations among a sample of young Black sexual minority men with HIV.

3. Roxana Rezai, PhD

Presentation Title: The Intersection of Place and Health: Neighborhood and Socio-Economic Determinants of Viral Suppression

Presentation Summary: Despite the availability of resources such as Ryan White-funded clinics that offer free access to HIV healthcare, significant disparities in viral suppression rates exist. This study examines the association between neighborhood characteristics, socioeconomic factors, and viral suppression among people living with HIV in neighborhoods served by Ryan White-funded clinics in Southern California.

 

Oral Panel 2 – Linkage and Retention Among People Living with HIV:

1. Hollie David, MPH

Presentation Title: Evaluating Linkages to Care among UCLA Patients with Detectable HIV Viremia

Presentation Summary: This study examines barriers to engagement in the HIV care continuum, focusing on patients at UCLA Health with detectable viral loads. By analyzing patient demographics, clinical characteristics, and care engagement, the study identifies factors like frequent visits and adherence to ART as key to achieving virologic suppression. Results suggest that increased healthcare interactions and timely follow-ups are crucial for improving engagement and retention in care, emphasizing the need for continued outreach and support for individuals living with HIV.

2. Wanjiku Dyer, MD Candidate and Czarina Kate Igama, MSc

Presentation Title: Reviewing Retention Rates & Medication Adherence Differences Between Differentiated Service Delivery Model and the RiseUP! Enhanced Differentiated Service Delivery (EDSD) Model for HIV Care & Treatment in Sub Saharan Africa

Presentation Summary: This presentation compares traditional Differentiated Service Delivery (DSD) models with the RiseUP! Enhanced Differentiated Service Delivery (EDSD) model for HIV care and treatment among adolescent girls and young women (AGYW) in Sub-Saharan Africa. We analyze retention rates and medication adherence across various countries, highlighting the effectiveness of the RiseUP! model’s holistic, youth-friendly approach. The study emphasizes the importance of tailored, community-based interventions in improving HIV care outcomes for vulnerable populations.

3. Ariana Waters, BS

Presentation Title: Analyzing Complex Pathways Between Resilience, Health, and Well-Being in Kenyan Youth Aged 15-24 Living with HIV in Informal Settlements

Presentation Summary: We conducted a cross-sectional survey to examine various pathways of resilience among HIV-positive youth living within informal settlements outside of Nairobi, Kenya. Relationships between variables were modelled and evaluated using linear regression analysis and structural equational modelling. We identified unique pathways linking social support, adverse childhood experiences, and HIV stigma to general health and resilience. These results may provide valuable insights for developing targeted intervention strategies to improve treatment adherence and HIV management in this population.

 

Oral Panel 3 – Testing, Prevention, and PrEP:

1. Katherine Lewis, MPH

Presentation Title: Violence and Coercion among Sex Workers in India: Gender Differences and PrEP Implications

Presentation Summary: We examined the relationship between violence/coercion and PrEP acceptability among cisgender female sex workers and transgender sex workers in urban West Bengal, India. We found very high rates of violence and coercion among participants, particularly among transgender sex workers. We also found that the relationship between coercion/violence and PrEP willingness was conditional on gender.

2. Dillon Trujillo, MPH

Presentation Title: Identifying Preferences for a Conditional Cash Transfer to Increase PrEP Use among MSM of Color in Los Angeles County

Presentation Summary: This study examines how to optimize a conditional cash transfer (CCT) intervention to increase PrEP use among Black and Latinx men who have sex with men (MSM) in Los Angeles County. Findings from a discrete choice experiment reveal preferences for larger cash payments provided more frequently, with some variation in PrEP modality. These results highlight the potential of tailored CCT designs to improve PrEP uptake and advance national efforts to reduce new HIV transmissions among key populations.

3. Brian Valencia, MPH

Presentation Title: Community Health Ambassador Program (CHAP): Evaluating the Success of a CDR SNS Strategy in LAC

Presentation Summary: In Los Angeles County (LAC), we implemented a cluster detection and response (CDR) social network strategy (SNS) among HIV molecular clusters with the goal of addressing service gaps and bringing individuals into HIV prevention and care, preventing further HIV transmission. SNSs have strong evidence of effectively reaching populations who may not otherwise test. The Community Health Ambassador Program (CHAP) used this strategy to distribute HIV self-test kits among the social, sexual, and behavioral networks of communities who may be at increased risk for HIV.

 

Oral Panel 4 – Impact of Policy on Research:

1. Nina T. Harawa, PhD, MPH and Charles Vignola, MPA and Michael Li, PhD

Presentation Title: Potential Implications of Key 2024 California Ballot Measures

Presentation Summary: Panel will discuss the potential impact of California ballot propositions that passed and did not pass on the well-being of individuals and communities that are affected by HIV, with a focus on those related to the criminal legal system.